Hans van Houte's most recent trade in Nurix Therapeutics Inc was a trade of 93,750 Employee Stock Option (right to buy) done . Disclosure was reported to the exchange on Feb. 10, 2026.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2026 | 93,750 | 93,750 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 10 Feb 2026 | 42,875 | 42,875 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 3,750 | 46,229 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 3,750 | 18,750 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 16.58 per share. | 30 Jan 2026 | 3,588 | 45,500 | - | 16.6 | 59,498 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 2,887 | 40,479 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 2,887 | 0 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 2,859 | 49,088 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 2,859 | 25,725 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 2,000 | 42,479 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2026 | 2,000 | 2,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 17.37 per share. | 30 Jan 2026 | 73 | 45,427 | - | 17.4 | 1,268 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.56 per share. | 03 Nov 2025 | 6,284 | 37,592 | - | 12.6 | 78,931 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 3,750 | 22,500 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 3,750 | 44,148 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.80 per share. | 30 Oct 2025 | 3,130 | 43,876 | - | 12.8 | 40,054 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 2,886 | 38,398 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 2,886 | 2,887 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 2,858 | 28,584 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 2,858 | 47,006 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 2,000 | 40,398 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2025 | 2,000 | 4,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.03 per share. | 01 Aug 2025 | 5,402 | 35,512 | - | 11.0 | 59,598 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.01 per share. | 30 Jul 2025 | 4,304 | 40,914 | - | 12.0 | 51,695 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 3,750 | 26,250 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 3,750 | 42,360 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 2,886 | 5,773 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 2,886 | 36,610 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 2,858 | 31,442 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 2,858 | 45,218 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 2,000 | 38,610 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2025 | 2,000 | 6,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | van Houte Hans | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.33 per share. | 02 May 2025 | 6,198 | 33,724 | - | 11.3 | 70,243 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 3,750 | 30,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 3,750 | 42,360 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 2,886 | 8,659 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 2,886 | 36,610 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.50 per share. | 30 Apr 2025 | 2,438 | 39,922 | - | 11.5 | 28,041 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 2,000 | 8,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2025 | 2,000 | 38,610 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 14.40 per share. | 03 Mar 2025 | 5,125 | 34,424 | - | 14.4 | 73,797 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 15.13 per share. | 03 Mar 2025 | 700 | 33,724 | - | 15.1 | 10,591 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 75,000 | 75,000 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Feb 2025 | 34,300 | 34,300 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 3,750 | 42,360 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 3,750 | 33,750 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 2,886 | 36,610 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 2,886 | 11,545 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 19.81 per share. | 30 Jan 2025 | 2,557 | 39,803 | - | 19.8 | 50,646 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 2,000 | 38,610 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2025 | 2,000 | 10,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.33 per share. | 30 Jan 2025 | 254 | 39,549 | - | 20.3 | 5,163 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 24.28 per share. | 01 Nov 2024 | 3,546 | 33,724 | - | 24.3 | 86,083 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2024 | 3,750 | 37,500 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2024 | 3,750 | 39,638 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2024 | 2,886 | 33,888 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2024 | 2,886 | 14,431 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 24.30 per share. | 30 Oct 2024 | 2,368 | 37,270 | - | 24.3 | 57,554 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2024 | 2,000 | 12,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2024 | 2,000 | 35,888 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 25.22 per share. | 26 Aug 2024 | 20,000 | 31,002 | - | 25.2 | 504,370 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 21.43 per share. | 01 Aug 2024 | 3,377 | 51,102 | - | 21.4 | 72,354 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 22.22 per share. | 01 Aug 2024 | 100 | 51,002 | - | 22.2 | 2,222 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2024 | 3,750 | 41,250 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2024 | 3,750 | 56,969 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2024 | 2,886 | 17,317 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2024 | 2,886 | 51,219 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.67 per share. | 30 Jul 2024 | 2,490 | 54,479 | - | 20.7 | 51,463 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2024 | 2,000 | 14,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2024 | 2,000 | 53,219 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 20.01 per share. | 20 Jun 2024 | 20,000 | 48,333 | - | 20.0 | 400,216 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.83 per share. | 02 May 2024 | 3,499 | 68,333 | - | 12.8 | 44,878 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 2,886 | 71,219 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 2,886 | 20,203 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 2,000 | 16,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2024 | 2,000 | 73,219 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 12.04 per share. | 30 Apr 2024 | 1,387 | 71,832 | - | 12.0 | 16,703 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 10.02 per share. | 16 Feb 2024 | 6,812 | 68,333 | - | 10.0 | 68,223 | Common Stock |
| Nurix Therapeutics Inc | van Houte Hans | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 150,000 | 150,000 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 45,000 | 45,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 2,886 | 23,089 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 2,886 | 74,816 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | van Houte Hans | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 2,000 | 76,816 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | van Houte Hans | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2024 | 2,000 | 18,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | van Houte Hans | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 7.99 per share. | 30 Jan 2024 | 1,671 | 75,145 | - | 8.0 | 13,352 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 20 Dec 2023 | 3,541 | 71,930 | - | 10.0 | 35,421 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 10.00 per share. | 19 Dec 2023 | 10,906 | 75,471 | - | 10.0 | 109,093 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2023 | 2,886 | 28,861 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2023 | 2,886 | 81,816 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2023 | 2,000 | 83,816 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jul 2023 | 2,000 | 22,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.65 per share. | 30 Jul 2023 | 1,245 | 82,571 | - | 9.7 | 12,020 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2023 | 2,886 | 31,747 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Apr 2023 | 2,886 | 79,651 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 9.88 per share. | 30 Apr 2023 | 721 | 78,930 | - | 9.9 | 7,121 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 88,900 | 88,900 | - | - | Employee Stock Option (right to buy) | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Feb 2023 | 24,000 | 24,000 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 2,886 | 77,689 | - | 0 | Common Stock | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Jan 2023 | 2,886 | 34,633 | - | - | Restricted Stock Units | |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Sale of securities on an exchange or to another person at price $ 11.78 per share. | 30 Jan 2023 | 924 | 76,765 | - | 11.8 | 10,884 | Common Stock |
| Nurix Therapeutics Inc | Hans van Houte | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 30 Oct 2022 | 2,886 | 37,519 | - | - | Restricted Stock Units |